Archive | Resource Library

This paper is geared toward parents of newly diagnosed autistic children and parents of young autistic children who are not acquainted with many of the basic issues of autism. Our discussion is based on a large body of scientific research.

Part 2 of this review will attempt to consolidate progress in integrative management of autism, aimed at improving independence and lifespan for people with the disorder.

Current pharmaceuticals fail to benefit the primary symptoms and can have marked adverse effects. Individualized, indepth clinical and laboratory assessments and integrative parent-physician-scientist cooperation are the keys to successful ASD management.

Suggestions are made for future therapeutic modalities addressing possible underlying causes of oxidative stress.

These findings indicate a possible role of increased oxidative stress and altered enzymatic antioxidants, both of which may be relevant to the pathophysiology of autism.

The results indicate that the trends in newly diagnosed NDs correspond directly to the expansion and subsequent contraction of the cumulative mercury dose to which children were exposed from TCVs through the U.S. immunization schedule.

It is hypothesized that HBOT therapy will improve symptoms in autistic individuals. A retrospective case series is presented that supports this hypothesis.

It is expected that amelioration of these underlying pathophysiological problems through the use of HBOT will lead to improvements in autistic symptoms.